The upsurge in R&D expenses primarily reflected the business’s expanded clinical development applications. Non-GAAP selling, general and administrative expenditures for Q2 2010 had been $50.1 million, compared to $37.6 million for Q2 2009. The upsurge in SG&A expenses primarily reflected costs associated with the expansion of the business’s operations worldwide. Second One fourth 2010 GAAP Financial Results: THE BUSINESS reported GAAP net gain for Q2 2010 of $21.8 million, or $0.24 per share, an increase of 30 % in comparison to $16.8 million, or $0.19 per share, in Q2 2009.The trials in non-dialysis sufferers, known as PEARL 1 and PEARL 2, are evaluating the safety and efficacy of Hematide compared to darbepoetin alfa in correcting anemia and preserving hemoglobin levels over time. In dialysis patients, the trials, called EMERALD 1 and EMERALD 2, are evaluating the protection and efficacy of Hematide and its capability to maintain hemoglobin levels in the prospective range when sufferers are switched from epoetin alfa or epoetin beta to Hematide.